Oxford BioDynamics (LON:OBD) Stock Price Up 14.7% – Still a Buy?

Shares of Oxford BioDynamics Plc (LON:OBD) were up 14.7% during trading on Thursday . The stock traded as high as GBX 0.59 ($0.01) and last traded at GBX 0.55 ($0.01). Approximately 5,249,994 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 27,810,600 shares. The stock had previously closed at GBX 0.48 ($0.01).

Oxford BioDynamics Stock Performance

The company has a current ratio of 0.68, a quick ratio of 2.80 and a debt-to-equity ratio of 370.22. The stock has a market cap of £10.28 million, a price-to-earnings ratio of -0.10 and a beta of 0.42. The stock’s 50 day moving average is GBX 0.63 and its two-hundred day moving average is GBX 1.82.

Oxford BioDynamics (LON:OBD) last announced its earnings results on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) earnings per share for the quarter. Oxford BioDynamics had a negative return on equity of 289.38% and a negative net margin of 1,800.32%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.